AC Immune (ACIU) Share-based Compensation (2015 - 2025)
AC Immune (ACIU) reported Share-based Compensation of $1.1 million for Q4 2025, up 2.46% year-over-year from $1.1 million in Q4 2024, and up 11.29% on a QoQ basis from $1.0 million in Q3 2025.
AC Immune (ACIU) has 11 years of Share-based Compensation data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Share-based Compensation rose 2.46% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.2 million (down 15.82% YoY) and the FY2025 annual result came in at $5.3 million, down 15.09% from the prior year.
- Share-based Compensation climbed to $1.1 million in Q4 2025 per ACIU's latest filing, from $1.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.2 million in Q1 2024 and bottomed at $574678.4 in Q3 2022.
- The 5-year median for Share-based Compensation is $1.1 million (2024), against an average of $1.2 million.
- The widest annual swing landed in 2022, when Share-based Compensation tumbled 61.96%; it then soared 70.8% in 2023.
- Tracing ACIU's Share-based Compensation over 5 years: stood at $1.1 million in 2021, then dropped by 18.57% to $922801.5 in 2022, then slipped by 2.63% to $898501.5 in 2023, then climbed by 22.85% to $1.1 million in 2024, then advanced by 2.46% to $1.1 million in 2025.
- Per Business Quant, the three latest ACIU Share-based Compensation figures stand at $1.1 million (Q4 2025), $1.0 million (Q3 2025), and $1.4 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 898,501.52 |
| Dec 31, 2023 | 898,501.52 |
| Sep 30, 2023 | 981,576.27 |
| Sep 30, 2023 | 981,576.27 |
| Jun 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | 1.59 Mn |
| Mar 31, 2023 | 1.59 Mn |
| Dec 31, 2022 | 922,801.48 |
| Dec 31, 2022 | 922,801.48 |
| Sep 30, 2022 | 574,678.43 |
| Sep 30, 2022 | 574,678.43 |
| Jun 30, 2022 | 931,348.83 |
| Jun 30, 2022 | 931,348.83 |
| Mar 31, 2022 | 1.07 Mn |
| Mar 31, 2022 | 1.07 Mn |
| Dec 31, 2021 | 1.13 Mn |
| Dec 31, 2021 | 1.13 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 917,893.64 |
| Jun 30, 2021 | 917,893.64 |
| Mar 31, 2021 | 947,892.62 |
| Mar 31, 2021 | 947,892.62 |
| Dec 31, 2020 | 1.12 Mn |
| Dec 31, 2020 | 1.12 Mn |
| Sep 30, 2020 | 1.34 Mn |
| Sep 30, 2020 | 1.34 Mn |
| Jun 30, 2020 | 1.03 Mn |
| Jun 30, 2020 | 1.03 Mn |
| Mar 31, 2020 | 880,837.30 |
| Mar 31, 2020 | 880,837.30 |
| Dec 31, 2019 | 815,379.59 |
| Dec 31, 2019 | 815,379.59 |
| Sep 30, 2019 | 895,187.10 |
| Sep 30, 2019 | 895,187.10 |
| Jun 30, 2019 | 559,489.73 |
| Jun 30, 2019 | 559,489.73 |
| Mar 31, 2019 | 586,372.51 |
| Mar 31, 2019 | 586,372.51 |
| Dec 31, 2018 | 624,002.40 |
| Dec 31, 2018 | 624,002.40 |
| Sep 30, 2018 | 592,554.85 |
| Sep 30, 2018 | 592,554.85 |
| Jun 30, 2018 | 723,359.93 |
| Jun 30, 2018 | 723,359.93 |
| Mar 31, 2018 | 634,752.50 |
| Mar 31, 2018 | 634,752.50 |
| Dec 31, 2017 | -833.59 Mn |
| Dec 31, 2017 | -833.59 Mn |
| Sep 30, 2017 | 856.12 Mn |
| Sep 30, 2017 | 856.12 Mn |
| Jun 30, 2017 | 202,999.74 |
| Jun 30, 2017 | 202,999.74 |
| Mar 31, 2017 | 99,596.35 |
| Mar 31, 2017 | 99,596.35 |
| Dec 31, 2016 | 967,023.63 |
| Dec 31, 2016 | 967,023.63 |
| Sep 30, 2016 | 153,768.09 |
| Sep 30, 2016 | 153,768.09 |
| Jun 30, 2016 | 103,063.81 |
| Jun 30, 2016 | 103,063.81 |
| Mar 31, 2016 | 38,262.87 |
| Mar 31, 2016 | 38,262.87 |
| Dec 31, 2015 | 57,600.32 |
| Dec 31, 2015 | 57,600.32 |